XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.

Abstract

AIM:

To investigate whether XRCC1 and ADPRT polymorphisms might be associated with outcomes of breast cancer.

METHODS:

A prospective study was conducted with a total of 335 breast cancer patients undergoing chemotherapy consecutively collected from Jan. 2005 to Jan. 2008. Genotyping of XRCC1 and ADPRT polymorphisms was conducted by PCR-RFLP assay.

RESULTS:

All 335 patients were followed up until death or the end of Jan. 2012, with a median follow-up period of 38.8 (2-64) months. It was shown that the variant genotype of XRCC1 399Gln/Gln was strongly significantly associated with a decreased risk of death from breast cancer, with an HR (95% CI) of 0.52 (0.28-0.91). Similarly, individuals carrying the ADPRT 762Ala/Ala demonstrated longer survival compared to ADPRT 762 Val/ Val, with an HR (95% CI) of 0.58 (0.31-0.97). Individuals with combination genotypes of XRCC1 399Gln allele and ADPRT 762Ala/Ala presented with a longer survival, the HR (95% CI) being 0.56 (0.32-0.97).

CONCLUSION:

We found a significant association between XRCC1399Gln/ Gln and ADPRT 762Ala/Ala polymorphisms and clinical outcomes. These two genotypes could be used as a surrogate markers of clinical outcome in glioma cases receiving chemotherapy.

• Authors: Sheng Ye, Jian Rong, Shao-Hong Huang, Zhou-San Zheng, Miao Yun, Shen-Ming Wang
• Journal: Asian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 13 Issue 10 Pg. 4923-6 ( 2012) ISSN: 2476-762X [Electronic] Thailand
• PMID: 23244082 (Publication Type: Journal Article)

Chemical References

• DNA-Binding Proteins
• X-ray Repair Cross Complementing Protein 1
• XRCC1 protein, human
• Epirubicin
• Doxorubicin
• Cyclophosphamide
• PARP1 protein, human
• Poly (ADP-Ribose) Polymerase-1
• Poly(ADP-ribose) Polymerases
• Fluorouracil

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, genetics, mortality)
• Cyclophosphamide (administration & dosage)
• DNA-Binding Proteins (genetics)
• Doxorubicin (administration & dosage)
• Epirubicin (administration & dosage)
• Female
• Fluorouracil (administration & dosage)
• Follow-Up Studies
• Genetic Predisposition to Disease
• Humans
• Middle Aged
• Neoplasm Staging
• Poly (ADP-Ribose) Polymerase-1
• Poly(ADP-ribose) Polymerases (genetics)
• Polymerase Chain Reaction
• Polymorphism, Genetic (genetics)
• Polymorphism, Restriction Fragment Length
• Prognosis
• Prospective Studies
• Survival Rate
• X-ray Repair Cross Complementing Protein 1